Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
157M
-
Number of holders
-
369
-
Total 13F shares, excl. options
-
98.4M
-
Shares change
-
+1.97M
-
Total reported value, excl. options
-
$3.88B
-
Value change
-
+$91.9M
-
Put/Call ratio
-
0.83
-
Number of buys
-
197
-
Number of sells
-
-150
-
Price
-
$39.43
Significant Holders of TG THERAPEUTICS, INC. - Common Stock (TGTX) as of Q1 2025
436 filings reported holding TGTX - TG THERAPEUTICS, INC. - Common Stock as of Q1 2025.
TG THERAPEUTICS, INC. - Common Stock (TGTX) has 369 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 98.4M shares
of 157M outstanding shares and own 62.55% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (21.5M shares), VANGUARD GROUP INC (15.6M shares), STATE STREET CORP (7.43M shares), GEODE CAPITAL MANAGEMENT, LLC (3.28M shares), Soleus Capital Management, L.P. (2.85M shares), Clearbridge Investments, LLC (2.64M shares), Pictet Asset Management Holding SA (2.4M shares), MORGAN STANLEY (2.05M shares), GOLDMAN SACHS GROUP INC (1.92M shares), and FMR LLC (1.74M shares).
This table shows the top 369 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.